高免赔额健康计划与儿童及成人哮喘控制药物使用及急性发作的关联
这项纵向队列研究采用双重差分设计,基于2002至2014年大型商业医保行政索赔数据,纳入持续哮喘的4至17岁儿童和18至64岁成人,比较转为高免赔额健康计划(HDHP)者与留在传统计划者的差异。在多数HDHP中哮喘药物免于免赔额,结果显示儿童仅ICS-LABA的30天配药率有显著绝对下降,成人无显著下降,两组口服激素冲剂和哮喘相关急诊就诊无统计学显著差异。
要点
- 在哮喘药物免于免赔额的HDHP中,儿童仅ICS-LABA年30天配药率显著绝对下降。
- 成人转为HDHP后任何控制药物的30天配药率均无显著下降。
- 儿童和成人的PDC、口服激素冲剂及哮喘相关急诊就诊均无统计学显著差异。
核心结论
- 在多数参保者哮喘药物免于免赔额的人群中,HDHP参保与儿童和成人控制药物使用极少或无下降相关,且哮喘急性发作无变化。
- 这些发现提示HDHP豁免哮喘药物免赔额可能有益。
研究设计与样本
- 采用双重差分设计的纵向队列研究,数据来自2002年1月1日至2014年12月31日大型全国商业(及Medicare Advantage)行政索赔数据库。
- 纳入24个月期间因雇主选择从传统计划转为HDHP或留在传统计划的4至17岁儿童和18至64岁成人持续哮喘患者。
- 使用粗化精确匹配技术平衡组间特征,包括雇主和参保者拥有HDHP的倾向。
主要发现
- 与对照组相比,转为HDHP的儿童仅ICS-LABA药物的年30天配药率有显著绝对下降(绝对变化,-0.04;95% CI,-0.07至-0.01)。
- 转为HDHP的成人任何控制药物的30天配药率均无显著下降。
- 儿童或成人的PDC、口服激素冲剂或哮喘相关急诊就诊均无统计学显著差异。
- 在9.9%的HDHP参保者中,其健康储蓄账户合格HDHP将药物纳入免赔额,与对照组相比ICS-LABA的PDC有显著绝对下降(-4.8%;95% CI,-7.7%至-1.9%)。
关键数值与推荐
- 在多数HDHP中,哮喘药物免于免赔额并需支付共付额。
- 主要结局指标为哮喘控制药物(吸入性糖皮质激素[ICS]、白三烯抑制剂和ICS长效β受体激动剂[ICS-LABA])的30天配药率和依从性(基于覆盖天数比例[PDC])。
- 哮喘急性发作通过控制药物使用者的口服激素冲剂率和哮喘相关急诊就诊率测量。
临床怎么用
- 对于转为HDHP的哮喘儿童和成人,若哮喘药物免于免赔额,控制药物使用和急性发作总体变化不大。
- 临床医生可关注HDHP中ICS-LABA配药率的轻微下降,尤其在药物纳入免赔额的计划中。
- 政策层面可考虑在HDHP中豁免哮喘药物免赔额以减少对控制药物使用的影响。
局限性
- 研究为观察性队列设计,可能存在残余混杂。
- 数据来自行政索赔数据库,可能受编码准确性影响。
- 结果主要适用于哮喘药物免于免赔额的HDHP人群,对药物纳入免赔额的计划需谨慎外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: High-deductible health plans (HDHPs) are increasingly common and associated with decreased medication use in some adult populations. How children are affected is less certain. OBJECTIVE: To examine the association between HDHP enrollment and asthma controller medication use and exacerbations. DESIGN, SETTING, AND PARTICIPANTS: For this longitudinal cohort study with a difference-in-differences design, data were obtained from a large, national, commercial (and Medicare Advantage) administrative claims database between January 1, 2002, and December 31, 2014. Children aged 4 to 17 years and adults aged 18 to 64 years with persistent asthma who switched from traditional plans to HDHPs or remained in traditional plans (control group) by employer choice during a 24-month period were identified. A coarsened exact matching technique was used to balance the groups on characteristics including employer and enrollee propensity to have HDHPs. In most HDHPs, asthma medications were exempt from the deductible and subject to copayments. Statistical analyses were conducted from August 13, 2019, to January 19, 2021. EXPOSURE: Employer-mandated HDHP transition. MAIN OUTCOMES AND MEASURES: Thirty-day fill rates and adherence (based on proportion of days covered [PDC]) were measured for asthma controller medications (inhaled corticosteroid [ICS], leukotriene inhibitors, and ICS long-acting β-agonists [ICS-LABAs]). Asthma exacerbations were measured by rates of oral corticosteroid bursts and asthma-related emergency department visits among controller medication users. RESULTS: The HDHP group included 7275 children (mean [SD] age, 10.8 [3.3] years; 4402 boys [60.5%]; and 5172 non-Hispanic White children [71.1%]) and 17 614 adults (mean [SD] age, 41.1 [13.4] years; 10 464 women [59.4%]; and 12 548 non-Hispanic White adults [71.2%]). The matched control group included 45 549 children and 114 141 adults. Compared with controls, children switching to HDHPs experienced significant absolute decreases in annual 30-day fills only for ICS-LABA medications (absolute change, -0.04; 95% CI, -0.07 to -0.01). Adults switching to HDHPs did not have significant reductions in 30-day fills for any controllers. There were no statistically significant differences in PDC, oral steroid bursts, or asthma-related emergency department visits for children or adults. For the 9.9% of HDHP enrollees with health savings account-eligible HDHPs that subjected medications to the deductible, there was a significant absolute decrease in PDC for ICS-LABA compared with controls (-4.8%; 95% CI, -7.7% to -1.9%). CONCLUSIONS AND RELEVANCE: This cohort study found that in a population where medications were exempt from the deductible for most enrollees, HDHP enrollment was associated with minimal or no reductions in controller medication use for children and adults and no change in asthma exacerbations. These findings suggest a potential benefit from exempting asthma medications from the deductible in HDHPs.
引用
- Galbraith AA, Ross-Degnan D, Zhang F, et al. Controller Medication Use and Exacerbations for Children and Adults With Asthma in High-Deductible Health Plans. JAMA Pediatr. 2021. PMID: 33970186. doi:10.1001/jamapediatrics.2021.0747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。